Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Status:
Completed
Trial end date:
2016-05-12
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Vel-Dex therapy (bortezomib and dexamethasone)
followed by autologous hematopoietic stem cell transplantation as an initial treatment in
patients with newly diagnosed AL.